- Home
- ARE vs AXSM Comparison
ARE vs AXSM Comparison
Compare ARE & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARE | AXSM |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.0B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARE | AXSM |
|---|---|---|
| Price | $50.46 | $154.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | $58.11 | ★ $209.18 |
| AVG Volume (30 Days) | ★ 1.7M | 472.6K |
| Earning Date | 04-27-2026 | 05-18-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,026,556,000.00 | N/A |
| Revenue This Year | N/A | $58.34 |
| Revenue Next Year | $0.52 | $54.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.10 | $86.99 |
| 52 Week High | $101.22 | $191.50 |
Technical Indicators
Market Signals| Indicator | ARE | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 30.40 |
| Support Level | $49.38 | $148.14 |
| Resistance Level | $54.86 | $191.13 |
| Average True Range (ATR) | 1.79 | 5.49 |
| MACD | -0.34 | -1.32 |
| Stochastic Oscillator | 29.58 | 6.36 |
Price Performance
Historical ComparisonAbout ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.